Distal myopathy

Distal myopathy refers to a clinically and genetically heterogeneous group of inherited muscular disorders characterized by progressive weakness and wasting that predominantly affects the distal muscles of the limbs — the hands, forearms, lower legs, and feet. Unlike many other myopathies that primarily involve proximal muscles (those closer to the trunk), distal myopathies initially spare the shoulder and hip girdle muscles, though proximal involvement may occur as the disease progresses. Several distinct subtypes are recognized, including Welander distal myopathy, Laing distal myopathy (MPD1), Nonaka distal myopathy (GNE myopathy/distal myopathy with rimmed vacuoles), Miyoshi myopathy, Udd distal myopathy (tibial muscular dystrophy), and Markesbery-Griggs late-onset distal myopathy, among others. Each subtype is associated with different genetic causes, inheritance patterns, and ages of onset. The skeletal muscular system is the primary body system affected. Patients typically present with difficulty walking, foot drop, trouble with fine motor tasks of the hands, or calf weakness depending on the specific subtype. Serum creatine kinase (CK) levels may be normal, mildly elevated, or markedly elevated depending on the form. Muscle biopsy findings vary by subtype and may show dystrophic changes, rimmed vacuoles, or myopathic features. Cardiac and respiratory involvement is uncommon in most subtypes but can occur in advanced disease. Electromyography (EMG) typically shows myopathic changes, and muscle MRI can help identify the pattern of muscle involvement, aiding in differential diagnosis. There is currently no cure for distal myopathies. Management is supportive and symptomatic, including physical therapy, occupational therapy, orthotic devices (such as ankle-foot orthoses for foot drop), and assistive devices to maintain mobility and function. Monitoring for potential cardiac or respiratory complications is recommended in certain subtypes. Genetic counseling is important for affected individuals and their families. Research into potential disease-modifying therapies, including gene therapy and substrate supplementation (e.g., sialic acid supplementation for GNE myopathy), is ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Distal myopathy